Heart failure in African Americans: Earlier onset, different etiologies, and poorer prognosis
- 23 Downloads
Heart failure (HF) is more prevalent in African Americans than in Caucasians, with an earlier age of onset and higher likelihood of nonischemic etiology and prior hypertension. Most studies show increased rates of hospitalizations in African Americans with HF, with similar overall survival. Clinical trials provide evidence of benefits with standard HF medical therapy in this population, including angiotensin-converting enzyme inhibitors and β-blockers. African Americans with HF derive substantial survival benefits with the fixed-dose combination of isosorbide dinitrate and hydralazine when added to other standard therapies. African American patients with HF receive similar quality of care in terms of certain HF medications but are less likely to receive HF education and counseling or implantable cardioverter defibrillators.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 1.American Heart Association: Heart Disease and Stroke Statistics. Dallas: American Heart Association; 2005. Available at http://www.americanheart.org/downloadable/heart/1200078608862HS_Stats%202008.final.pdf. Accessed March 6, 2008.Google Scholar
- 14.Shekelle PG, Rich MW, Morton SC, et al.: Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003, 41:1529–1538.PubMedCrossRefGoogle Scholar
- 15.Hunt SA: ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005, 46:e1–e82.PubMedCrossRefGoogle Scholar
- 22.Taylor AL, Ziesche S, Yancy CW, et al.: Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial. Circulation 2007, 115:1747–1753.PubMedCrossRefGoogle Scholar
- 25.Yancy CW, Abraham WT, Albert NM, et al.: Defining the natural history and improving quality of care for African Americans hospitalized with heart failure: a report from the organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF). Circulation 2005, 112:II–506.Google Scholar